Roger Badia
Post-doctoral researcher
HIV Pathogenesis
Spain
Biography
Roger Badia is a post-doctoral researcher at IrsiCaixa under a Sara Borrell fellowship awarded by the Carlos III Health Institute (ISCIII). He holds a PhD in Immunology from the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona (IBB-UAB). His research focuses on the molecular mechanisms underlying host-pathogen interaction. Genome editing using CRISPR-Cas9 is the day-to-day toolbox he uses to study cellular cofactors and restriction factors implicated in the HIV replication cycle. Outside the lab he enjoys playing with his daughters, having fun with the guitar, playing rugby and being with his friends.
Research Interest
Clinical immunology , Biotechnology, Molecular biology
Publications
-
Roger Badia, Eva Riveira-Muñoz, Bonaventura Clotet, José A. Esté, Ester Ballana; Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1, Journal of Antimicrobial Chemotherapy, Volume 69, Issue 7, 1 July 2014, Pages 1755–1759,
-
Permanyer, M., Pauls, E., Badia, R., Esté, J. A., & Ballana, E. (2013). The Cortical Actin Determines Different Susceptibility of Naïve and Memory CD4+ T Cells to HIV-1 Cell-to-Cell Transmission and Infection. PLoS ONE, 8(11), e79221.
-
Raimon Puig de la Bellacasa,a Albert Gibert,a Jesús M. Planesas,a Laia Ros-Blanco,a Xavier Batllori,a Roger BadÃa,b Bonaventura Clotet,b José Esté,b Jordi Teixidóa and José I. Borrell*a Org. Biomol. Chem., 2016,14, 1455-1472
-
Pauls, E., Ruiz, A., Riveira-Muñoz, E., Permanyer, M., Badia, R., Clotet, B., … Este, J. A. (2014). p21 regulates the HIV-1 restriction factor SAMHD1. Proceedings of the National Academy of Sciences of the United States of America, 111(14), E1322–E1324.
-
Badia, R., Angulo, G., Riveira-Muñoz, E., Pujantell, M., Puig, T., Ramirez, C., … Esté, J. A. (2016). Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1. Journal of Antimicrobial Chemotherapy, 71(2), 387–394.
